Skip to content
Clinical Trials – home
GreeceBack to Greece

Clinical trials in Peristeri – page 75

1 033 clinical trials in Peristeri, Greece. Every trial is listed in the EU Clinical Trials Register and updated daily.

GreeceOur site in GreeceΚλινικεσΔοκιμεσ.gr(opens in a new tab)
Peristeri at a glance
1 033
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 033 trials in Peristeri

Open in trial search

C3 glomerulopathy

Not recruiting

Study on the Effectiveness and Safety of Iptacopan for Patients with Complement 3 Glomerulopathy

Investigational
Countries:GreeceGreece
  • Participants:0–17 years · 18–64 years
  • Substances:Iptacopan
  • Sponsor:Novartis Pharma AG

Plasma cell myeloma+13

Not recruiting

Study on Atezolizumab and Drug Combinations for Advanced Malignancies in Patients from Previous Atezolizumab Trials

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Alectinib
  • Sponsor:F. Hoffmann-La Roche AG

Asthma

Not recruiting

Study on the Long-term Effects of Dupilumab in Preventing Lung Function Decline in Adults with Uncontrolled Moderate to Severe Asthma

Investigational
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Dupilumab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Dry eye+1

Not recruiting

Study on the Effectiveness and Safety of Ianalumab for Patients with Active Sjögren’s Syndrome

Registered drug
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Ianalumab
  • Sponsor:Novartis Pharma AG

Study on MK-2060 for Preventing Blood Clots in Dialysis Patients with End-Stage Kidney Disease

Investigational
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:MK-2060
  • Sponsor:Merck Sharp & Dohme LLC

Study of Atezolizumab and Tiragolumab Compared to Durvalumab for Patients with Advanced Non-Small Cell Lung Cancer After Chemoradiation

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:F. Hoffmann-La Roche AG

Study Comparing Trastuzumab Deruxtecan and Trastuzumab Emtansine for Patients with High-Risk HER2-Positive Breast Cancer with Residual Disease After Initial Treatment

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Trastuzumab Deruxtecan
  • Sponsor:Daiichi Sankyo Inc.

Breast cancer

Not recruiting

Study on Alpelisib and Fulvestrant for Men and Postmenopausal Women with Advanced HR-positive, HER2-negative Breast Cancer with PIK3CA Mutation

Registered drug
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Alpelisib
  • Sponsor:Novartis Pharma AG

Study Comparing Adagrasib and Docetaxel for Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Adagrasib
  • Sponsor:Mirati Therapeutics Inc.

Study on Caplacizumab and Immunosuppressive Therapy for Adults with Immune-Mediated Thrombotic Thrombocytopenic Purpura

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Caplacizumab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Study on the Safety and Effectiveness of Crinecerfont for Adults with Classic Congenital Adrenal Hyperplasia

Investigational
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Crinecerfont
  • Sponsor:Neurocrine Biosciences Inc.

Study on Long-term Safety and Efficacy of Cipaglucosidase Alfa and Miglustat for Adults with Late-onset Pompe Disease

InvestigationalNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Cipaglucosidase Alfa
  • Sponsor:Amicus Therapeutics Inc.

Other cities in Greece

The busiest research cities in the country

All 48 cities in Greece

Clinical research in Peristeri

What the registry says about research in the country

01 Cardiovascular Diseases

In Peristeri, researchers are evaluating a weekly injectable agent for patients with HFpEF or HFmrEF who also have obesity, aiming to lower the combined risk of cardiovascular death and heart‑failure hospitalisations.

  • Composite cardiovascular outcome assessment
  • Weekly dosing strategy
  • Integration with standard of care
  • Focus on heart‑failure subtypes

Both studies are actively recruiting, involve 25 investigators, and seek to improve treatment options for a growing heart‑failure population.

02 Nutritional and Metabolic Diseases

Clinical trials in the city are comparing two formulations of injectable cagrilintide and a placebo, as adjuncts to diet and activity counseling, to achieve meaningful weight loss in participants with excess body weight.

  • Weight‑loss non‑inferiority testing
  • Superiority versus placebo evaluation
  • Adjunct lifestyle intervention
  • Targeting overweight and obesity

The recruiting studies involve a dedicated team of investigators and aim to expand therapeutic options for metabolic health.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.